Healthcare in 2022 Will Be Subjective
Clinical research is the heart of clinical medicine. It defines what we know. More importantly, it defines how we think....
Healthcare in 2022 Will Be Irrational
We consider progress in healthcare as a march towards efficiency. But efficiency is limited by patient behavior, which can be...
Healthcare in 2022 Will Be Complex
Healthcare is complex. We like simple. So we try to make healthcare simple, which has worked for now, but not...
Vaccine Mandates Strike at the Heart of Patient Autonomy
Much has been said about the resistance to vaccine mandates. But beneath the rhetoric is the core issue - the...
The App is Now Your Doctor
Healthcare innovators assume patients trust healthcare technology. But trust in technology wanes when patients lose autonomy. So instead of trust,...
Harm Reduction Means Patient Education
The government can right many wrongs by focusing on harm reduction policies to combat the rising number of deaths by...
Abortion is a Right, but Roe is Wrong
Abortion is defined as a right to privacy in Roe v. Wade. The ruling protects a fundamental right but it...
The Omicron Narrative
The new variant is upon us and the narrative has been set, repeating many of the familiar reactions we have...
Where to Receive COVID-19 Treatment
As much as we discuss the drugs used to treat COVID-19, few know where to receive them should they develop...
Is Europe a Leading Indicator for COVID-19?
As we enter the second pandemic winter, we look for signs indicating whether COVID-19 will worsen. Europe has typically served...
Exceptions to Common Sense Law
The courts recently ruled vaccine mandates as unconstitutional and against public interests. But by emphasizing economic interests over public health...
Of Thoughts and Language
The push for healthcare equity has profoundly changed the way we view healthcare, including how we speak in medical settings....
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more